The persistent puzzle of long COVID may have found an unexpected ally in diabetes medicine cabinets. While millions continue grappling with lingering symptoms months after initial infection, new evidence suggests a common metabolic drug could offer meaningful protection against this debilitating condition.
The ACTIV-6 trial enrolled nearly 3,000 adults who received either metformin or placebo within seven days of COVID-19 symptom onset, then tracked their recovery for six months. Among participants taking the 14-day metformin course, clinician-diagnosed long COVID occurred in significantly fewer cases, with a risk ratio of 0.495 compared to placebo. The drug demonstrated a 96% posterior probability of preventing long COVID diagnosis, while self-reported persistent symptoms at 180 days showed more modest but consistent reductions.
This finding aligns with metformin's established anti-inflammatory and metabolic regulatory properties, which researchers increasingly recognize as relevant to post-viral recovery. The drug's ability to modulate cellular energy metabolism and reduce systemic inflammation may interrupt the pathological cascades that lead to prolonged symptoms. However, the study's relatively low overall long COVID incidence—just 2.6% at six months—reflects a population that was largely vaccinated and previously infected, potentially limiting generalizability to higher-risk groups.
While promising, this represents early evidence for metformin's role beyond diabetes management. The mechanism remains unclear, and the modest absolute risk reduction means large numbers would need treatment to prevent individual cases. Still, given metformin's established safety profile and low cost, these results warrant serious consideration for early COVID treatment protocols, particularly as we continue seeking tools to prevent long-term complications.